X-ZELL launches Global Technology Trial

Leipzig, June 2024 – To celebrate the 45th anniversary of the European Congress of Cytology (ECC) in Leipzig, Germany, X-ZELL has announced the launch of an international Technology Trial program.

X-ZELL Founder & CEO, Dr Sebastian Bhakdi, unveiled the new partnership program on Monday alongside Scientific Advisor, Dr Achim Battmann, who pioneered the adoption of X-ZELL’s Next-Generation Cytology technology in routine cytopathology.

“The X-ZELL Next-Generation Cytology platform is now listed with the US FDA and has the CE-mark for both IVDR and MDR,” Dr Bhakdi explained. “To evaluate the system’s effectiveness in routine laboratory environments, we are now seeking visionary cytology experts to follow in Dr Battmann’s footsteps and test the system in a real-world setting.”

“To evaluate the system’s effectiveness in routine laboratory environments, we are now seeking visionary cytology experts to […] test the system in a real world setting.”
Dr. Sebastian C.P. Bhakdi

According to Dr Bhakdi, selected participants will enjoy full access to X-ZELL’s award-winning technology and scientific development team and have the opportunity to present their independent feedback at relevant international conferences in 2025 and 2026.

X-ZELL Next-generation Cytology (NGC) is the first immunostaining solution specifically designed to streamline cytopathological analyses of serous fluid and fine-needle aspirates. Challenging conventional immunohisto- and cytochemistry, it fuses X-ZELL’s powerful Cryoimmunostaining™ technology with a novel digital imaging solution to make cytopathology more efficient than ever before.

“Next-Generation Cytology really is a powerful new tool to maximise diagnostic yield from cytological samples.”
Dr. Achim Battmann

“Next-Generation Cytology really is a powerful new tool to maximise diagnostic yield from cytological samples,” commented Dr Battmann, co-owner and chief pathologist at MVZ Frankfurt in central Germany. “The system can accommodate up to eight fluorescent antibodies on the same microscope slide and help us turn around samples in less than 4 hours by omitting the traditional cell-blocking process. That way we extract much more detailed information per sample while benefitting from a significant efficiency advantage.”

Professionals interested in joining the Technology Trial program may contact X-ZELL at info@x-zell.com. Terms and Conditions apply.

—

Media Contact
Sebastian Grote
sebastian.g@x-zell.com

About X-ZELL
X-ZELL is an award-winning medical technology company pioneering the field of next-generation cytology. The company’s mission is to transform cancer diagnostics by fusing novel laboratory technology with digital imaging to detect and visualise individual atypical cells in minimally invasive body liquids and digitize them for instant on-screen analysis. Founded by Y Combinator finalist, Dr Sebastian C.P. Bhakdi, X-ZELL was ranked second-most innovative healthcare start-up in the world in 2020 and has since won the coveted MedTech Innovator APAC competition as well as the Abstract Award at the 2021 European Conference of Cytology.